network member

Rutgers Cancer Institute of New Jersey

195 Little Albany Street, Room 5513, New Brunswick, NJ, 08903
Rutgers Cancer Institute of New Jersey

About Network Member

Rutgers Cancer Institute of New Jersey, first called “The Cancer Institute of New Jersey,” was born in 1993, became a National Cancer Institute (NCI) -designated Cancer Center in 1997, and achieved Comprehensive Cancer Center status in 2002, the highest and most prestigious designation from the NCI held by only a few dozen such centers. The Cancer Institute of New Jersey integrated into Rutgers University on July 1, 2013, and became an independent unit within the university as a result of the New Jersey Medical and Health Sciences Education Restructuring Act. As New Jersey’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey in partnership with RWJBarnabas Health has a team of internationally recognized physicians and researchers driven by a singular focus and mission, to help individuals fight cancer. Through the transformation of laboratory discoveries into clinical practice, we target cancer with precision medicine, immunotherapy, and clinical trials and provide the most advanced, comprehensive cancer care to adults and children. Rutgers Cancer Institute physicians and scientists work side by side to make sure the most sophisticated treatments are delivered to our patients quickly and safely — the future of cancer treatments today. Rutgers Cancer Institute offers world-class quality cancer care providing the most advanced treatment options for patients in its New Brunswick facility, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. Enhancing the delivery of services on the New Brunswick campus will be the completion of the Jack and Sheryl Morris Cancer Center — a 12-story, 510,000-square-foot cancer hospital expected in 2024. Expert teams at Rutgers Cancer Institute include dedicated specialists including medical oncologists, surgical oncologists, radiation oncologists, social workers, nutritionists, and nurses identify and meet the needs of the individual patient. Each multidisciplinary team focuses on a specific disease and is led by a physician who is a clinical and academic expert in the cause and treatment of that disease. Multidisciplinary, clinical programs at the Rutgers Cancer Institute include: Stacy Goldstein Breast Cancer Center, Gastrointestinal/Hepatobiliary Oncology Program, Fannie E. Rippel Center for Women’s Reproductive Cancers, Leukemia/Lymphoma/Hematologic Malignancies, Liver Cancer and Bile Duct Cancer Care Program, Blood and Marrow Transplant Program, Head and Neck Oncology Program, Cardio-Oncology Program, Endocrine and Neuroendocrine Program, Lung Cancer Program, Melanoma Oncology Program, Sarcoma and Soft Tissue Oncology Program, Neuro-oncology Program, Pediatric Hematology/Oncology Program, Phase I/Developmental Therapeutics Program, Prostate Cancer Program, Thoracic Oncology Program, and Urologic Oncology Program. Rutgers Cancer Institute operates under a “consortium cancer center” partnership as identified by the NCI allowing for formal scientific and academic collaboration with Princeton University. This model unites the best researchers from across the state with one goal: to eradicate cancer. Research at Rutgers Cancer Institute is currently being conducted in areas of behavioral science, precision medicine, tumor immunology, autophagy, drug development and resistance, the relationship between cellular and genetic alterations and tumor development, cancer control and prevention, bioinformatics, and cancer genomics. There are several types of clinical trials currently underway at the Rutgers Cancer Institute including treatment, prevention, screening, and behavioral/quality of life. Website: Rutgers Cancer Institute of New Jersey Contact: For more information about clinical trials at Rutgers Cancer Institute of New Jersey, call 732-235-7356 or search here for a clinical trial.  
Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
New York University Cancer Institute
Orlando Health Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Health-West
University of Michigan Rogel Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Cancer areas:Lung
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Moffitt Cancer Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Virginia Commonwealth University
Currently Enrolling

BTCRC-LYM20-463

A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Cancer areas:Lymphoma
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

HCRN-GI16-288

A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288
Cancer areas:Colorectal
Cleveland Clinic Cancer Center
Knight Cancer Institute at Oregon Health & Science University
Rutgers Cancer Institute of New Jersey
Sylvester Comprehensive Cancer Center at the University of Miami
The Ohio State University
University of Kansas Medical Center
Enrollment Closed

HCRN-GU16-287

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer
Huntsman Cancer Institute at the University of Utah
Icahn School of Medicine at Mount Sinai
Rutgers Cancer Institute of New Jersey
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vanderbilt-Ingram Cancer Center
Enrollment Closed

BTCRC-BRE16-042

A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
Michigan State University
New York University Cancer Institute
Rutgers Cancer Institute of New Jersey
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-GI15-067

A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067
Cancer areas:Pancreatic
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Penn State Cancer Institute
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
Enrollment Closed

BTCRC-GI20-457

A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial) Big Ten Cancer Research Consortium BTCRC-GI20-457
Cancer areas:Liver and Bile Duct
DHR Health
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
New York University Cancer Institute
Rutgers Cancer Institute of New Jersey
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-LUN19-396

A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
New York University Cancer Institute
Penn State Cancer Institute
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
Summit Health Cancer Center
The Ohio State University
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center